REGENLABS®
THE FUTURE OF MEDICINE®

NeuroDrive®

CLINICAL APPLICATIONS

- Increases neurotransmitters in the brain
- Source of antioxidants to protect brain cells
- Increases alpha brain waves
- Strengthens synapses

Centrophenoxine treatment in a mammalian study significantly increased maximum lifespan by 26.5%. Studies show its antioxidant activity can reduce oxidative stress in the brain.

Salidroside is the main active nootropic in Rhodiola supporting long term improvements in memory and recall. Studies demonstrate neuroprotective effects and its ability to improve cognitive function.

Trans-Ferulic Acid works to enhance both memory and learning ability due to its cerebral antioxidant effects.

BRAIN

DISCUSSION

Regen Lasbs NeuroDrive® has a proprietary blend of Centrophenoxine, Salidroside, and Trans-Ferulic Acid. The combination of these ingredients greatly improves memory and learning. In addition, NeuroDrive® contains several other potent ingredients proven to enhance cognition, including Bacopa, L-Tyrosine & Phosphatidylserine 20% Amino Acid,

Bacopa Monnieri Extract comes from the ancient Bacopa herb, which helps improve memory and reduce anxiety.

L-Tyrosine is a form of the amino acid tyrosine, which helps improve memory and thinking skills, cope with sleep deprivation, and boost mental sharpness.

Phosphatidylserine is a naturally occurring lipid that Covers and protects cells in the brain to promote healthy cognitive function.

All of these ingredients within NeuroDrive® work together to reduce brain fog, enhance cognitive function, reduce oxidative stress, and increase your body's natural ability to fight memory loss.

NUTRITION FACTS

SUPPLEMENT FACTS
Serving Size: 2 Capsules
Servings Per Container: 30

	Amount Per Serving	%DV
NeuroDrive® Brain Formula	**500mg**	*
3% Standardized Salidroside (from 300mg of Rhodiola Root Extract) Centrophenoxine		
Bacopa Monnieri Aerial Part Powder	**400mg**	*
Trans-Ferulic Acid 98% (Synthetic)	**400mg**	*
L-Tyrosine	**200mg**	*
Phosphatidylserine 20% Amino Acid	**150mg**	*

*Daily Value Not Established

OTHER INGREDIENTS: Vegetable capsules, Rice Hulls, Rice Flour

DIRECTIONS: Take 2 capsules daily or as needed. Do not exceed more than 2 capsules in a 24h period.

+These statements have not been evaluated by The Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

REGENLABS®
THE FUTURE OF MEDICINE®

NeuroDrive®

REFERENCES

1. Hidese S, Ogawa S, Ota M, et al.Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Function in Healthy Adults: A Randomized Controlled Trail. Nutrients. 2019;11(10):2362. Published 2019 Oct 3. doi:10.3390/ nu11102362
2. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313-326. doi:10.1089/rej.2013.1431
3. Kumar N, Pruthi V. Potential applications of ferulic acid from natural sources. Biotechnol Rep (Amst). 2014;4:86-93. Published 2014 Sep 16. doi:10.1016/j.btre.2014.09.002
4. Butterworth RF. Thiamin deficiency and brain disorders. Nutr Res Rev.2003;16(2):277-284. doi:10.1079/NRR200367
5. Marcer D, Hopkins SM. The differential effects of meclofenoxate On memory loss in the elderly. Age Ageing.1977;6(2):123-131. doi:10.1093/ageing/6.2.123
6. Glees P, Spoerri PE. Centrophenoxine-induzierter Abbau und Abtransport von Lipofuszin. Eine alektronenmikroskopische Studie [Centrophenoxin-induced dissolution and removal of lipfuscin. An electron microscopic study (author's transl)]. Arzneimittelforschunig. 1975;25(10):1543-1548
7. Marcer D, Hopkins SM. The differential effects of meclofenoxate On memory loss in the elderly. Age Ageing.1977;6(2):123-131. doi:10.1093/ageing/6.2.12
8. Oliver JE, Restell M. Serial testing in assessing the effect of meclofenoxate on patients with memory defects. Br J Psychiatry. 1967;113(495):219 222. doi:10.1192/bjp. 113.495.219
9. Ito H, Kudo Y, KabeshimaY, Nobushima S, Komine K. Double-blind controlled trial of lucidril (meclofenoxate) in the pst traumatic syndrome, especially dizziness. Folia Psychiatry Neurol Jpn. 1968;22(1):23-42. doi:10.1111/j.1440-1819.1968.tb01307.x
10. Pék G Fülöp T, Zs-Nagy I. Gerontopsychological studies using NAI ('Nürnberger Alters-Inventor') on patients with organic psychosyndrome (DSM III, Category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Arch Gerontol Geriatr. 1989;9(1):17-30. doi:10.1016/0167-4943(89)90021-6
11. Popa R, Schneider F, Mihalas G, et al. Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia). Arch Gerontol Geriatr. 1994;19 Suppl 1:197-206. doi:10.1016/S0167-4943(05)80065-2
12. Dubois B, Zaim M, Touchon J, et al. Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer's disease. J Alzheimers Dis. 2012;29(3):527-535. doi:10.3233/JAD 2012-111370
13. Mosharrof AH, Petkov VD, Petkov VV. Effects of medclofenoxate And citicholine on learning and memory in aged rats. Acta Physiol Pharmacol Blug.1987;13(4):17-24.
14. Petkov VD, Mosharrof AH, Petkov VV. Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). Acta Physiol Pharmacol Bulg. 1988;14(1):3-13.
15. Voronina TA, Garibova TL, Trofimov SS, Sopyev ZhA, Petkov VD, Lazarova MB. Comparative studies on the influence of ONK (N(5-hydroxynicotinoil) glutamic acid), piracetam and meclofenoxate on the learning- and memory-impairing effect of scopolamine, clonidine, and methergoline. Acta Physiol Pharmacol Bulg. 1997;17(4):8-16.
16. Nehru B, Bhalla P, Garg A. Evidence for centrophenoxine as a protective drug in aluminum induced behavioral and biochemical alteration in rat brain. Mol Cell Biochem-.2006;290(1-2):33-42. goi:10.1007/s11010-006-9125-7
17. Liao Y, Wang R, Tang XC. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal Degeneration in rats. Acta Pharmacol Sin. 2004;25(12):1590-1596
18. Zs-Nagy I. On the role of intracellular physicochemistry in quantitative gene expression during aging and the effect of centrophenoxine. A review. Arch Gerontol Geriatr. 1989;9(3):215-229. doi:10.1016/0167-4943(89)90042-3
19. Sharma D, Maurya AK, Singh R. Age-related decline in multiple unit action potentials of CA3 region of rat hippocampus: correlation with lipid peroxidation and lipofuscin concentration and the effect of centrophenoxine. Neurobiol Aging. 1993;14(4):319-330. doi:10.1016/16/0197-4580(93)90117-t
20. Hochschild R. Effect of dimethylaminoethyl p-chlorophenoxyacetate on the life span of male Swiss Webster Albino mice. Exp Gerontol. 1973;8(4):177-183. doi:10.1016/0531 5565(73)90024-7
21. Nehru B,Verma R, Khanna P, Sharma SK. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res. 2008;1201:122-127. doi:10.1016/j.brainres.2008.01.074
22. Patro N, Sharma SP, Patro IK. Lipofuscin accumulation in ageing myocardium & its removal by meclophenoxate. Indian J Med Res.1992;96:192-198
23. Spoerri PE, Glees P, El Ghazzwai E. Accumulation of lipofuscin in the myocardium of senile guinea pigs: dissolution and removal of lipofuscin following dimethylaminoethyl p-chlorophenoxyacetate administration. An electron microscopic study. Mech Ageing Dev. 1974;3(5-6):311-321. doi:10.1016/0047-6374(74)90027-x
24. Parson SJ, Russell SD, Bennett MK, et al. Increased lipofuscin on endomyocardial biopsy predicts greater cardiac improvements in adolescents and young adults. Cardiovasc Pathol. 2012;21(4):317-323. doi:10.1016/j.carpath.2011.11.002
25. Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(7):1099-1107. doi:10.1016/j.pnpbp.2004.05.045
26. Fisher MC, Zeisel SH, Mar MH, Sadler TW. Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro. FASEBJ. 2002;169(6):619-621. doi:10.1096/fj.01-0564fje
27. Merchenthaler I, Lane M, Sabins G, et al. Treatment with an orally bioavailable prodrug of 170-estradiol alleviates hot flushes without hormonal effects in the periphery. Sci Rep. 2016;6:30721. Published 2016 Aug 1. doi: 10.1038/srep30721
28. Riga S, Riga D, Schneider F. Prolongevity medicine: Antagonic-Stress drug in distress, geriatrics, and related diseases. II. Clinical Review-2003. Ann N Y Acad Sci. 2004;1019:401-405. doi:10.1196/ annals.1297.072